September 21, 2005 08:00 ET

DUSA Pharmaceuticals, Inc. to Present at UBS Global Life Sciences Conference

WILMINGTON, MASSACHUSETTS--(CCNMatthews - Sept. 21, 2005) - DUSA Pharmaceuticals, Inc. (NASDAQ NMS:DUSA) announced today that Dr. Geoffrey Shulman, the Company's Chairman & CEO and Mr. Robert Doman, the President & COO will be presenting on Monday, September 26th at 3:30 p.m. (Eastern) at the UBS Global Life Sciences Conference taking place at The Grand Hyatt New York.

To access the live audio broadcast or the subsequent archived recording, log on to http://www.dusapharma.com. The archived version of the webcast will be available online for one month.

DUSA Pharmaceuticals, Inc. is a biopharmaceutical company engaged primarily in the development and marketing of Levulan Photodynamic Therapy (PDT) and Photodetection (PD) for multiple medical conditions, with a primary focus on dermatology. PDT and PD utilize light-activated compounds to induce a therapeutic or detection effect. DUSA is a world leader in topically or locally applied PDT and PD. DUSA maintains offices in Wilmington, MA, Valhalla, NY and Toronto, Ontario.

Except for historical information, this news release contains certain forward-looking statements that involve known and unknown risk and uncertainties, which may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the statements made. These forward-looking statements relate to a planned presentation by Dr. Geoff Shulman and Mr. Robert Doman and the availability of the presentation on the web. Such risks and uncertainties include, but are not limited to, commencement of the conference, ability of Dr. Shulman and Mr. Doman to be present at the conference, and other risks identified in DUSA's SEC filings from time to time.

Contact Information

  • DUSA Pharmaceuticals, Inc.
    Shari Lovell
    Director, Shareholder Services
    (416) 363-5059